作者: Rafael Rosell , Laia Perez-Roca , Jose Javier Sanchez , Manuel Cobo , Teresa Moran
DOI: 10.1371/JOURNAL.PONE.0005133
关键词:
摘要: Background Median survival is 10 months and 2-year 20% in metastatic non-small-cell lung cancer (NSCLC) treated with platinum-based chemotherapy. A small fraction of non-squamous cell cancers harbor EGFR mutations, improved outcome to gefitinib erlotinib. Experimental evidence suggests that BRCA1 overexpression enhances sensitivity docetaxel resistance cisplatin. RAP80 Abraxas are interacting proteins form complexes could modulate the effect BRCA1. In order further examine mutations mRNA levels on advanced NSCLC, we performed a prospective non-randomized phase II clinical trial, testing hypothesis customized therapy would confer over non-customized therapy. an exploratory analysis, also examined levels.